Information Provided By: 
Fly News Breaks for February 6, 2017
ARAY
Feb 6, 2017 | 06:43 EDT
Aegis analyst Jason Wittes initiated Accuray (ARAY) with a Buy and a $7 price target saying Radixact, the next-generation TomoTherapy platform, was approved for 510k in June, and brings up to par with Varian's (VAR) True Beam and Elekta's Axesse machines. Wittes said Accuray is well positioned to take on its first major replacement cycle over the next three years, which we expect to add 40-50 systems a year to its current run rate of 60-70 systems.
News For ARAY From the Last 2 Days
There are no results for your query ARAY
